Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02860000
Title Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

Her2-receptor negative breast cancer

Therapies

Alisertib + Fulvestrant

Alisertib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.